




Product Introduction

Epirubicin HCl

Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase.

Technical Data:

Molecular Weight (MW):	579.98	
Formula:	C ₂₇ H ₂₉ NO ₁₁ ·HCl	
Solubility (25°C) * <1 mg/ml means slightly soluble or insoluble:	DMSO 116 mg/mL	
	Water 116 mg/mL	
	Ethanol 3 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder 6 months -80°C in DMSO	
CAS No.:	56390-09-1	

Biological Activity

Epirubicin, like doxorubicin, exerts its antitumor effects by complex with DNA, resulting in damage to DNA and interference with the synthesis of DNA, RNA, and proteins. Epirubicin may also affect the integrity and activity of cellular membranes. Maximal cell kill caused by Epirubicin occurs during the S phase of the cell cycle. With higher concentrations effects are also seen in early G2 as well as G1 and M phases. ^[1] Epirubicin display antineoplastic activity against most cancer cells. Epirubicin is cytotoxic to Hepatoma G2 cells with IC50 of 1.6 µg/mL at 24hr. 1.6 µg/mL Epirubicin induces apoptosis of Hep G2 cells, and higher

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

activity of catalase by 50%, Se-dependent glutathione peroxidase by 110%, Cu, Zn-superoxide dismutase by 172% and Mn-superoxide dismutase by 135%. Epirubicin increases the cellular expression of NADPH-CYP 450 reductase, and reduces GST- π expression. [2]

Epirubicin are clinically active against a broad range of tumor types, including breast cancer, malignant lymphomas, soft tissue sarcomas, lung cancer, pleural mesothelioma, gastrointestinal cancer, head and neck cancer, ovarian cancer, prostatic carcinoma, transitional bladder carcinoma and so on. [3] Epirubicin at a dose of 3.5 mg/kg suppresses tumor mass of human breast tumor xenograft R-27 by 74.4 %. [4]

References

- [1] Cersosimo RJ, et al. J Clin Oncol, 1986, 4(3), 425-439.
- [2] Ozkan A, et al. Pol J Pharmacol, 2004, 56(4), 435-444.
- [3] Bonadonna G, et al. Ann Oncol, 1993, 4(5), 359-369.
- [4] Asanuma F, et al. Folia Microbiol (Praha), 1998, 43(5), 473-474.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.